Category: Regenerative Treatments
-
Why PRP Results Vary: Platelet Dose and Preparation Quality
PRP is not one product. Platelet dose, leukocyte profile, red cell contamination, and pre-activation change what reaches the joint, and what the studies show.
-
What happens during a physician-led Clinical Evaluation at Regen.MD
A data review before the session, a 60-minute physician-led root-cause discussion, and a written terrain roadmap naming the bottlenecks and the sequence.
-
When orthobiologics are not the right treatment: how we decide what fits
In a 2026 survey of 357 orthopaedic patients, 66.9% believed orthobiologics could treat cartilage injuries. How we decide when an injection does not fit.
-
Tennis elbow and orthobiologics: what the evidence shows, and which patients the trials left out
PRP results for tennis elbow depend on when you measure and who was enrolled. The trial-by-trial eligibility and exclusion criteria, stated plainly.
-
Subchondral bone marrow lesions on knee MRI: what they mean, and why they matter for osteoarthritis risk
In a MOST analysis of 395 knees, 66% of bone marrow lesions changed size over 30 months and half resolved. How to read the finding on your report.
-
Tendon PRP versus intra-articular PRP: different targets, different evidence
Level I evidence supports PRP in rotator cuff tears and discourages it in Achilles and patellar tears. Why the injection target decides what the data mean.
-
Realistic recovery timelines after orthobiologic treatment
Why there is no single recovery schedule after PRP, BMAC or Lipogems, what the phases actually are, and the survey data on what patients wrongly expect.
-
Returning to resistance training after an orthobiologic procedure
A staged return-to-lifting plan after PRP, BMAC or Lipogems: readiness checks, three loading stages, knee and disc modifications, and the signs that mean stop.
-
Sacroiliac joint dysfunction: what orthobiologics can and cannot be expected to do
SI joint pain drives 15-25% of back pain, yet only 45% of fusion patients had a diagnostic injection first. Why confirmation comes before PRP or BMAC.
-
Plantar fasciopathy: orthobiologic options when standard care fails
Heel pain that did not respond to first-line care: where PRP, BMAC and Lipogems actually sit in the published treatment sequence, and what has to be confirmed first.
-
Protein intake and resistance training to protect muscle as you age
How much protein, distributed how, and how often to lift — the sourced numbers behind protecting muscle after 30, and what to do when joint pain is the real limit.
-
Osteoporosis, bone quality, and joint degeneration: how bone strength and regenerative options fit together
Osteoporosis affects 12.6% of US adults aged 50 and over, and low bone mass a further 43.1%. What that means when you are being evaluated for a degenerating joint.
-
PRP versus BMAC versus Lipogems: how the choice is actually made
The three are not interchangeable. The selection follows the tissue target, and one randomized knee trial compared BMAC, PRP, and hyaluronic acid over 12 months.
-
Partial rotator cuff tear: non-surgical and orthobiologic options, and how we approach care
Most studies report around 75% success with non-operative treatment of rotator cuff tears. What that aggregate means, and where orthobiologics genuinely enter.
-
Nicotine and smoking effects on tendon and bone healing: what they do to your recovery and how to plan treatment
Nicotine reduced vascularity and left healed tendon 44.7% weaker in a rat model. In human bone-forming cells it was whole smoke, not nicotine, that did the damage.
-
Kellgren-Lawrence knee osteoarthritis grading: what your grade actually means
Your Kellgren-Lawrence grade describes what a knee X-ray shows, not how much pain you feel. What grades 0 to 4 mean, and how reliable the number really is.
-
Leukocyte-poor versus leukocyte-rich platelet-rich plasma: why the formulation matters
In knee osteoarthritis, leukocyte-rich and leukocyte-poor PRP have not separated on pain or function, but local reactions differ. What the trial evidence says.
-
Lipogems and micro-fragmented adipose tissue, explained
How micro-fragmented adipose tissue is processed, what the published cluster sizes are, and what it is not claimed to do for an arthritic knee.
-
Intraosseous subchondral PRP for knee osteoarthritis: what it is and who it is for
PRP placed into subchondral bone, not just the joint space. What the randomized trials on both sides show, who they excluded, and why it is a bridge and not cartilage repair.
-
How orthobiologics are prepared, and why processing standards matter
Orthobiologics are made from your own blood, marrow, or fat. How collection, timing, sterility, and injection target change what ends up in the syringe.
-
GLP-1 medications and muscle loss: what to watch for in 2026
A 2026 meta-analysis of 821 adults on obesity-dose GLP-1 receptor agonists reported a mean 1.74 kg fall in absolute lean mass. What that means for your plan.
-
Gluteal tendinopathy and lateral hip pain: orthobiologic options in 2026
Tendon pathology is present in 88% to 98% of lateral hip pain and isolated bursitis in about 2%. What that changes about which orthobiologic is worth discussing.
-
Facet arthropathy and regenerative options for spinal pain: what to know in 2026
Facet joints are the pain source in 15% to 41% of patients with chronic low back pain. What confirming that changes, and where orthobiologics honestly fit.
-
Bone Marrow Aspirate Concentrate (BMAC): What It Is and What It Is Not
BMAC is an autologous concentrate, and it does not regrow or regenerate cartilage. What a 2025 narrative review establishes about knee osteoarthritis, and what it does not.
-
Cervical facet pain and regenerative approaches to the neck
Cervical facet pain: one randomized PRP trial, three series, and the metabolically complex patients every one of them screened out. St. Louis.
-
Achilles Tendinopathy: Orthobiologic and Non-Surgical Options in 2026
Across 9 trials of insertional Achilles tendinopathy, overall certainty for non-surgical care was very low. What that means before you consider an injection.
-
Advanced knee osteoarthritis: when PRP is a bridge, not a substitute
In 90 patients with grade 3-4 knee osteoarthritis on arthroplasty waiting lists, two PRP injections beat steroid and NSAID at six months. A bridge, not a swap.
-
Orthobiologics in St. Louis: Repairing the System Instead of Silencing the Alarm
There is a fire alarm going off in the building, and the standard response has been to argue with the alarm. Turn it down. Change the batteries. Put tape over the speaker. What almost never happens is someone…
-
Intradiscal PRP: The Protocol for Treating the Disc as Biology, Not Hardware
The prevailing model treats your spine as a mechanical structure — a stack of parts, one of which has worn out. That framing determines everything that follows: image it, find the worn part, numb it or remove it.…
-
Shockwave Therapy for Chronic Tendon Pain: How Pressure Waves Restart a Stalled Repair
If you have been told your only remaining option is surgery, there is a technology worth understanding before you accept that framing. First, a clarification, because the word “shockwave” has been diluted by marketing. This is not the…
-
Red Light Therapy vs. Class IV Laser: Why a Skin Panel Cannot Reach Your Disc
If you have spent several hundred dollars on a red light panel hoping it would help your back, your hip, or an arthritic joint — and it has not — you were not sold a fraud. You were…
-
Whole Body Vibration for Joint Pain: Why the Gym Plate Did Nothing for Your Knees
If you have stood on the vibration plate at your gym hoping it would do something for your knees, your back, or your hips — and stepped off with nothing to show for it — the machine was…
-
Using an HSA for PRP and Stem Cell Therapy: The Opportunity and the Trap
You asked about platelet-rich plasma. About bone marrow concentrate. About real regenerative treatment for a chronic, degenerative problem. And your insurance company gave you the answer it always gives: experimental, investigational, denied. What that denial does not tell…
